Dataset Information

COVID-19 vaccine-related frequently asked questions (FAQs) by people with epilepsy and carers in Iran; educational video is included.

ABSTRACT:

Objective

The aim of the current study was to inquire the questions and concerns of people with epilepsy (PWE) about COVID-19 vaccines in order to provide a more realistic list of their frequently asked questions (FAQs).

Methods

We surveyed all the consecutive PWE or their care-givers who were referred to our neurology clinics (Shiraz University of Medical Sciences) during January-February 2022. We collected their questions and concerns in relation to COVID vaccines based on a predesigned brief questionnaire. Informed consent to participate in the study was obtained from the participants.

Results

In total, 452 people participated in the study; 291 people (64.4%) did not have any questions or concerns with regard to the COVID-19 vaccination. Having any questions or concerns about COVID-19 vaccination was significantly associated with not being vaccinated. Questions and concerns about the adverse effects of COVID-19 vaccines [seizure worsening, general adverse effects, long-term effects (e.g., infertility, cognitive dysfunction)] were by far the most common questions by people with epilepsy and their carers.

Conclusion

Our findings may be used by policy-makers to prepare appropriate educational materials to provide the best targeted and tailored information to people with epilepsy and their carers to convince them of the necessity and safety of COVID-19 vaccination. Such an educational material must include enough information on the associated adverse effects of COVID-19 vaccines and should also discuss some other important issues such as indications of these vaccines in special populations and drug-vaccine interactions.

SUBMITTER: Asadi-Pooya AA

PROVIDER: S-EPMC9117255 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Interventions: Pre-intervention: All participants logged on to a website from a location most convenient for them, using a personally-allocated ID, and completed a single-session baseline survey that took approximately 15 minutes to complete. The primary dependent measure collected was readiness to act on perceived personal colorectal cancer risk. Two weeks later following completion of the baseline survey, participants logged on again to the website from a convenient location. Participants were randomized to 1 of 4 groups, 3 intervention arms and one control, using pre-allocated ID numbers that had previously been block randomised. A computer algorithm restricted the availability of each website to the prescribed cohort, dependent upon the ID entered. Each intervention comprised a single website session lasting approximately 30 minutes (dependent upon the time taken by the participant to review the information presented). Intervention: A description of each intervention follows: Arm 1: FAQs: The FAQs website opened with a page entitled Prevention of Bowel Cancer” and provided 6 icons that could be clicked on to Get answers to some of the most Frequently Asked Questions by people in certain age groups”. Each icon included a picture of a man or woman selected to be representative of the age group together with words identifying gender and age (e.g., I am a woman aged 35–49”). Clicking on the icon took the participant to a page that provided a further link to information to satisfy the top information needs of this group as previously identified . This page started with the five most frequently asked questions” for the specified cohort and associated links to answers and was followed below by links to OTHER questions asked…” This latter set of questions was also ordered by order of importance as identified . Arm 2: The LIST website was also entitled Prevention of Bowel Cancer”. It was followed by the statement, The information I want about bowel cancer is…” and a list of 10 links ordered according to the chronology of cancer diagnosis and treatment, with the exception of prevention being included at the end. Arm 3: The CHOICE website included both the LIST of information links and the FAQs icons on the initial page with the instruction Get answers to some of the most Frequently Asked Questions by people in certain age groups, or view a list of categories of information about bowel cancer”. The location of the icons and the list was balanced so that half of CHOICE respondents viewed the icons on the right side of the screen and the list on the left, whereas the other half viewed the reverse order. Once a selection had been made, participants were treated as though they were assigned to the FAQs or LIST condition.

Project description:BackgroundRheumatologists must contend with COVID-19 pandemic in the management of their patients and many questions have been raised on the use of both anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARD). The French Society of Rheumatology (SFR) selected the most critical ones to the daily practice of a rheumatologist and a group of 10 experts from SFR and Club Rheumatism and Inflammation (CRI) boards proposed responses based on the current knowledge of May 2020.MethodsFollowing the availability of the first 18 questions and statements, 1400 individuals consulted the frequently asked questions between the March 31, 2020 and April 12, 2020. As a result, 16 additional questions were forwarded to the SFR, and answered by the board. An additional round of review by email and video conference was organized, which included updates of the previous statements. The scientific relevance of 5 of the questions led to their inclusion in this document. Each response received a final assessment on a scale of 0-10 with 0 meaning no agreement whatsoever and 10 being in complete agreement. The mean values of these votes for each question are presented as the levels of agreement (LoA) at the end of each response. This document was last updated on April 17, 2020.ResultsBased on current scientific literature already published, in most circumstances, there is no contraindication to the initiation or continuation of anti-inflammatory drugs as well as DMARDs. If signs suggestive of infection (coronavirus or other) occur, treatments should be discontinued and resumed, if necessary, after 2 weeks without any symptoms. Only, some signals suggest that people taking an immunosuppressive dose of corticosteroid therapy are at greater risk of developing severe COVID-19. Intra-articular injections of glucocorticoids are allowed when there is no reasonable therapeutic alternative, and providing that precautions to protect the patient and the practitioner from viral contamination are adopted, included appropriate information to the patient.ConclusionsCurrently available data on managing patients with rheumatic diseases during the COVID-19 pandemic are reassuring and support continuing or initiating symptomatic as well as specific treatments of these diseases, the main target of their management remaining their appropriate control, even during this pandemic.